



EIKO LIFESCIENCES LIMITED

F E E L T H E C H E M I S T R Y

Ref. No.: EIKO/BSE/2021-22/25

Dated: 02nd November 2021

To,
Corporate Services Department,
BSE Limited,
P J Towers, 1st Floor,
Dalal Street, Fort, Mumbai - 400001.

Sub: Outcome of Board Meeting held today i.e., November 02, 2021.

Ref: Eiko LifeSciences Limited

BSE Scrip Code: EIKO 540204

Dear Sir/Madam,

Pursuant to the Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), and amendments thereto, this is to inform that the Meeting of the Board of Directors of the Company held today i.e., on Tuesday, 02nd November 2021 at 4.00 P.M. the Board, inter-alia, considered and approved the Unaudited Financial Results for the Quarter and half year ended 30th September 2021

The Statutory Auditors have carried out a "Limited Review" of the Unaudited Financial Results for the Quarter and half year ended 30th September 2021

Further, Pursuant to the Regulation 33 of the Listing Regulations, we are enclosing herewith a copy of the Unaudited Financial Results and Limited Review Report of the Statutory Auditors of the Company

The said results shall be published in one English and one vernacular newspaper as required.

This intimation is also available on the Company's website at www.eikolifescienceslimited.com

The meeting of Board of Directors concluded at 4.27 P.M

Please take the same on your records.

Thanking you.
Yours Sincerely,

For **EIKO LIFESCIENCES LIMITED**

Avi Mundecha
Company Secretary
ACS-65529

Encl: same as above

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER 2021

(₹ In Lakhs)

Sr. No.	Particulars	Quarter ended			Half year ended		Year ended
		30.09.2021	30.06.2021	30.09.2020	30.09.2021	30.09.2020	31-03-2021
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Revenue from operations	609.43	844.54	7.02	1,453.97	14.68	1,199.06
	Other income	19.43	12.65	2.03	32.08	2.03	46.03
	Total revenue	628.86	857.19	9.05	1,486.04	16.70	1,245.08
2	Expenses						
	Cost of Material consumed	539.86	740.86	-	1,280.71	-	1,061.20
	Employee benefits expense	5.19	8.64	1.38	13.83	2.83	11.83
	Depreciation and amortization expense	16.06	9.27	1.54	25.34	3.08	6.16
	Finance Cost	18.57	4.55	0.69	23.12	1.40	8.78
	Other expenses	19.93	40.24	1.74	60.17	3.27	73.85
	Total expenses	599.60	803.57	5.35	1,403.17	10.58	1,161.81
3	Profit/(Loss) from ordinary activities before tax	29.26	53.62	3.70	82.88	6.12	83.27
4	Tax expense:						
	(1) Current tax	1.80	5.77	0.46	7.56	1.10	22.08
	(2) Earlier year's Tax	0.25	-	0.10	0.25	0.09	0.03
	(4) Deferred tax	5.34	7.73	(0.02)	13.06	(0.04)	(0.27)
5	Profit/(Loss) from ordinary activities after tax	21.88	40.12	3.16	62.00	4.96	61.43
6	Other Comprehensive Income (OCI)						
	<u>Item that will not be reclassified to profit or loss</u>						
	Gain/(Loss) on recognised on fair valuation of Financial Assets	(1.24)	(0.06)	(1.83)	(1.30)	(4.70)	11.99
	Income tax relating to these items	0.31	0.01	0.48	0.33	1.23	(3.02)
	Total Other Comprehensive Income (OCI)	(0.93)	(0.04)	(1.35)	(0.97)	(3.47)	8.98
	Profit/(Loss) for the Period	20.95	40.08	1.81	61.03	1.49	70.41
	Paid up Equity Share Capital (Face Value of Rs. 10 each)	831.63	831.63	382.00	831.63	382.00	382.00
7	Earnings Per Share (EPS) (Not annualised)						
	(1) Basic	0.15	0.64	0.08	0.42	0.13	1.61
	(2) Diluted	0.15	0.64	0.08	0.42	0.13	1.61

**Notes:**

1. The above Financial Results for the quarter and half year ended 30th September 2021 have been reviewed and recommended by Audit Committee and has been approved by the Board of Directors at its Meeting held on Tuesday, 2nd November 2021. The Statutory Auditors have carried out Limited Review of above results and expressed an unmodified opinion on these financial results.
2. The Company has single business segment namely "Speciality & Fine Chemicals" therefore in the context of Ind As 108, disclosure of segment information is not applicable.
3. Paid up Share Capital of the company has increased from ₹3.82 Crore to ₹8.32 Crore on account of issue and allotment of 24,29,967 Equity Shares having a face value of ₹10/- each, at ₹30/- per share aggregating to ₹7,28,99,010/- issued for cash and 20,66,300 equity shares having a face value of ₹10/- each, issued at ₹70/- per share aggregating to ₹14,46,41,000/- for consideration other than cash on a preferential basis.
4. During the quarter, the difficulties faced in the supply chain management resulted into lower business volumes. However, the situation is improving now and expected to normalize.
5. Previous quarter figures have been regrouped reclassified wherever necessary, to make them comparable.

For Eiko Lifesciences Limited

Laxmikant Kabra
Chairman & Director
DIN: 00061346

Place: Thane

Date: 2nd November 2021



Disclosure of Assets and Liabilities as per Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as of 30th September 2021

(₹ in Lakhs)

Particulars	As of 30-09-2021	As of 31-03-2021
ASSETS		
Non-current assets		
Property, Plant and Equipment	1,464.10	24.75
<u>Financial Assets</u>	-	-
Investments	20.66	21.95
Loans	279.11	361.15
Other Financial Assets	221.38	180.98
Deferred Tax Asset	-	2.37
	1,985.24	591.19
Current assets		
Inventories	463.73	6.35
<u>Financial Assets</u>	-	-
Trade Receivables	431.62	341.47
Cash and cash equivalents	343.48	407.20
Other Current Financial Assets	91.12	315.19
Other Current Assets	6.27	-
	1,336.21	1,070.21
TOTAL ASSET	3,321.46	1,661.40
EQUITY AND LIABILITIES		
EQUITY		
Equity Share capital	831.63	382.00
Other Equity	2,023.42	236.62
Share Application Money Pending for Allotment	-	634.00
	2,855.05	1,252.61
LIABILITIES		
Non-current liabilities		
<u>Financial Liabilities</u>		
Non-Current Borrowings	16.28	175.87
Deferred Tax Liabilities	10.37	-
	26.65	175.87
Current liabilities		
<u>Financial Liabilities</u>		
Current Borrowing	327.00	-
Trade payables	101.53	189.50
Other financial liabilities	5.92	8.53
Current Tax Liabilities	-	4.90
Provisions	5.31	29.99
	439.76	232.93
TOTAL LIABILITIES	3,321.46	1,661.40

For Eiko Lifesciences Limited

L.K. Kabra

Laxmikant Kabra
Chairman & Director
DIN: 00061346



Date: 2nd November 2021
Place: Thane

Disclosure of cashflow as per Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for 30th September 2021

(₹ in Lakhs)

Particulars	Period Ended 30.09.2021	Year ended 31.03.2021
A. CASH FLOW FROM OPERATING ACTIVITIES		
Net (loss) / profit before tax	82.88	83.27
Adjustments for		
Depreciation and Amortisation Expense	25.34	6.16
Finance Costs	23.12	8.78
Interest Income classified as investing cash flow	-	(35.79)
Operating profit before working capital changes	131.33	62.42
Working capital adjustments: -		
Increase / (Decrease) in Trade and Other Payables	(87.98)	189.47
Increase / (Decrease) in Provisions	(24.68)	28.73
Increase / (Decrease) in Other Financial Liabilities	(2.61)	2.34
(Increase) / Decrease in Inventories	(457.38)	(6.35)
(Increase) / Decrease in Trade Receivables	(90.15)	(341.47)
(Increase) / Decrease in Other Financial Assets	187.99	(343.10)
(Increase) / Decrease in Other Current Assets	(6.27)	0.51
Cash generated from / (used in) operations	(349.74)	(407.45)
Direct taxes paid (Net of Refunds)	(17.03)	(18.15)
Net cash (used in) / from generated from operating activities	(366.77)	(425.60)
B. CASH FLOW FROM INVESTING ACTIVITIES		
Additions in Property, Plant & Equipment	(18.28)	-
Sale/ (Purchase) of Investments	(0.01)	40.25
Loans and Advances	82.04	(26.50)
Interest Income	-	35.79
Net cash (used in) / generated from investing activities	63.76	49.55
C. CASH FLOW FROM FINANCING ACTIVITIES		
Proceeds from issue of shares	94.99	634.00
Interest paid	(23.12)	(8.78)
Proceeds from short term borrowings	327.00	-
Repayment of long-term borrowings (net)	(159.59)	156.27
Net cash (used in) / from financing activities	239.29	781.49
Net decrease in cash and cash equivalents (A+B+C)	(63.73)	405.44
Cash and cash equivalents at the beginning of the year	407.20	1.76
Cash and cash equivalents at the end of the year	343.48	407.20

For Eiko Lifesciences Limited

L.K. Kabra

Laxmikant Kabra
Chairman & Director
DIN: 00061346



Date: 2nd November 2021
Place: Thane





Independent Auditor's Review Report on the Quarterly and Half Yearly ended Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

**To the Board of Directors
Eiko Lifesciences Limited
(Formerly known as Narendra Investments (Delhi) Limited)**

1. We have reviewed the accompanying statement of unaudited financial results of **Eiko Lifesciences Limited** (Formerly known as Narendra Investments (Delhi) Limited) (the "Company") for the quarter and Half Year ended September 30, 2021 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial result prepared in accordance with applicable Principles laid down in Indian Accounting Standards 34 "Interim Financial Reporting" ("Ind AS 34") prescribed under section 133 of companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015 read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement

For Thanawala & Company
Chartered Accountants
Firm Reg. No.: 110948W


CA Vijay Thanawala
Proprietor
Membership No.: 015632



Place: Mumbai
Date: 2nd November 2021

UDIN: 21015632AAAAEE6222